Could changing the order of two cancer drugs boost their power?
NCT ID NCT07285850
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving the drug bevacizumab alone first, then adding atezolizumab later, works better than giving both drugs together from the start. It involves 20 adults with advanced liver cancer who also have fatty liver disease. The goal is to see if the sequential approach improves tumor shrinkage and survival while keeping side effects manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab and atezolizumab (drugs given by IV)
What this could lead to
If successful, this could point toward a more effective way to treat advanced liver cancer in people with fatty liver disease, potentially improving response rates and survival.
What could go wrong
This is a small early-phase trial with only 20 participants, so results may not apply widely. The drugs can cause serious side effects like bleeding or immune reactions, and the sequential approach may not prove better than the standard combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, Shanghai Municipality, 201805, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••